Navigation Links
Cystic fibrosis patients may breathe easier, thanks to bioengineered antimicrobials
Date:9/25/2007

searchers then developed a computational model to mimic the biological system. The model accurately predicted the structure of the actin-lysozyme bundles, and agreed quantitatively with the small-angle X-ray scattering experiments, said Erik Luijten, a professor of materials science and engineering, and of physics, as well as a researcher at the Beckman Institute and the other corresponding author of the PNAS paper.

The next step was to find a way to liberate the lysozyme, or prevent it from binding in the first place. Using their model, the researchers explored the consequences of varying the positive charge on the lysozyme.

When we reduced the charge, we found a huge effect in our model, Luijten said. The lysozyme would not bind to the actin. It floated around independently in the mucus.

Then, through genetic engineering, the researchers made lysozyme with roughly half the normal charge. Experiments confirmed the simulations; the reduced charge prevented lysozyme from sticking to actin, without significantly reducing the all-important antimicrobial activity.

Although much work remains, future cystic fibrosis patients might use an inhaler to deliver genetically modified charge-reduced antimicrobials to upper airways. There, these non-stick antimicrobials would go to work killing bacteria, and mitigate against long-term infection.

The implications of this research extend into other areas as well. In water purification, for example, one of the steps involves putting positively charged molecules in the water to grab negatively charged pollutants. The resulting aggregates settle to the bottom of holding tanks and are removed from the water supply.

A better understanding of how oppositely charged molecules bind in aqueous environments could lead to ways of removing emerging pathogens in water purification, Wong said.


'/>"/>

Contact: James E. Kloeppel
kloeppel@uiuc.edu
217-244-1073
University of Illinois at Urbana-Champaign
Source:Eurekalert

Page: 1 2

Related biology news :

1. Scientists discover basic defect in cystic fibrosis airway glands
2. Study reveals how cells destroy faulty proteins in cystic fibrosis
3. Discovery could aid fight against cystic fibrosis infection
4. Clues to gene expression in cystic fibrosis will guide research
5. Key found to kill cystic fibrosis superbug
6. Penn study on lung-infecting bacterial enzyme suggests new approach to cystic fibrosis treatment
7. Gene expression patterns predict rapid decline in idiopathic pulmonary fibrosis patients
8. Extra-aggressive form of idiopathic pulmonary fibrosis identified
9. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
10. HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs
11. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... solar panels that repels grime and dirt? Expanded battery ... Aviv University research, just published in Nature Nanotechnology ... nano-scale level that could make these futuristic visions come ... the range of 100 nanometers (roughly one-billionth of a ...
(Date:12/3/2009)... can undergo a personality change in warmer water, according to ... some species more aggressive. , Experiments with two species of ... the first time that some reef fish are either consistently ... even more marked as water temperatures rise. , A slight ...
(Date:12/3/2009)... UPTON, NY A team of scientists from the ... University, and the Indian Institute of Science has made ... genetic information in DNA that is necessary to carry ... December 1, 2009 edition of Nature Structural & ...
Breaking Biology News(10 mins):A window that washes itself? 2Fish with attitude: Some like it hot 2Grooving down the helix 2Grooving down the helix 3Laboratory Test May Predict Effectiveness of ERBITUX 28R 29 for Individual Colorectal Cancer Patients 12384 1Laboratory Test May Predict Effectiveness of ERBITUX 28R 29 for Individual Colorectal Cancer Patients 12384 2Laboratory Test May Predict Effectiveness of ERBITUX 28R 29 for Individual Colorectal Cancer Patients 12384 3Cimzia 28R 29 28certolizumab pegol 29 Provides Long Term Remission and Response Rates in Infliximab Refractory Crohns Patients 12382 1Cimzia 28R 29 28certolizumab pegol 29 Provides Long Term Remission and Response Rates in Infliximab Refractory Crohns Patients 12382 2Cimzia 28R 29 28certolizumab pegol 29 Provides Long Term Remission and Response Rates in Infliximab Refractory Crohns Patients 12382 3Cimzia 28R 29 28certolizumab pegol 29 Provides Long Term Remission and Response Rates in Infliximab Refractory Crohns Patients 12382 4Cimzia 28R 29 28certolizumab pegol 29 Provides Long Term Remission and Response Rates in Infliximab Refractory Crohns Patients 12382 5Cimzia 28R 29 28certolizumab pegol 29 Provides Long Term Remission and Response Rates in Infliximab Refractory Crohns Patients 12382 6Cimzia 28R 29 28certolizumab pegol 29 Provides Long Term Remission and Response Rates in Infliximab Refractory Crohns Patients 12382 7Cimzia 28R 29 28certolizumab pegol 29 Provides Long Term Remission and Response Rates in Infliximab Refractory Crohns Patients 12382 8Cimzia 28R 29 28certolizumab pegol 29 Provides Long Term Remission and Response Rates in Infliximab Refractory Crohns Patients 12382 9Cimzia 28R 29 28certolizumab pegol 29 Provides Long Term Remission and Response Rates in Infliximab Refractory Crohns Patients 12382 10Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 1Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 2Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 3Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 4Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 5
... of societys most pressing environmental problems, from climate change ... natural chemical cycles. Moving toward a sustainable future will ... a huge impact on the Earths chemistry. , ... Studies, Dr. William H. Schlesinger, who has been investigating ...
... treating post trauma, the U.S. armed forces face challenges on ... Department of Defense (DoD) research conference to address such issues ... Conference Center. , The purpose of the conference ... services and representatives, as well as showcase UH research expertise ...
... at New Mexico State University recently discovered the worlds ... pepper originating in Assam, India, has earned Guiness World ... blasting past the previous champion Red Savina. In replicated ... one million SHUs, almost double the SHUs of Red ...
Other Biology News:Biogeochemistry -- A window into the Earth's ecological health 2US Army, US Navy, US Air Force, US Marines, US Department of Defense conference held at UH 2US Army, US Navy, US Air Force, US Marines, US Department of Defense conference held at UH 3
(Date:12/4/2009)... Therapeutics, Inc. today announced that data from pre-clinical studies of ... in vitro and animal models of human chronic myeloid ... upcoming 51st Annual Meeting of the American Society of Hematology ... 2009. The poster will be presented by Stemline,s collaborators at ...
(Date:12/3/2009)... INC. (OTC Bulletin Board: ACCP), ... of MuGard, an FDA approved treatment for oral mucositis, ... MuGard is commercially launched by Access, partner, SpePharm, in ... Greece and Sweden. Access is conducting pre-marketing activities, including ...
(Date:12/3/2009)... Inverness Medical Innovations, Inc. (NYSE: IMA ), a ... health at home through the merger of rapid diagnostics and ... on its Series B Convertible Perpetual Preferred Stock ( IMA-PB). ... stock in an amount per share equal to the quotient ...
(Date:12/2/2009)... Blue Steel is emerging as one of the fastest growing ... True Green Energy Group and True Green Planet,s President and ... business for over 25 years, stated that Spectrum Blue Steel ... stage for spectacular earnings because of the bi products recovered ...
Breaking Biology Technology:Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3
... Program for KOS-1584, HAYWARD, Calif., Oct. ... ) today announced that Roche and Kosan ... collaborative research, development and,commercialization agreement entered into ... period, following which Kosan will reacquire worldwide,rights ...
... Sigma-Aldrich(TM) (Nasdaq:,SIAL), a life science company dedicated ... world,s researchers, and Oxford,BioMedica (LSE: OXB), a leading ... key order confirming the strength and validity of,intellectual ... in,the research field to Sigma-Aldrich. The ruling was ...
... In Vitro Data presented at AACR-NCI-EORTC International ... Molecular Targets and Cancer Therapeutics in ... /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(TSX: AEZ; Nasdaq: ... therapy and oncology, today presented an abstract ...
Other Biology Technology:Kosan to Reacquire Epothilone Program From Roche 2Kosan to Reacquire Epothilone Program From Roche 3Kosan to Reacquire Epothilone Program From Roche 4Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 2Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 3AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 2AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 3AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 4
Human Serpin A8/AGT Affinity Purified Polyclonal Ab Keywords: Ang II, AngII, Hypertension, Salt Homeostasis, Pre-eclampsia...
Homo sapiens retinoid X receptor, alpha...
Human Serpin B5/Maspin Affinity Purified Polyclonal Ab...
... 19 x 29 cm, 1. One ... staining of Coomassie Blue or silver-stain gels ... blots for high sensitivity ECL detection and ... volume, and processing time.Proven design for consistent, ...
Biology Products: